Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dialysis patients may get safer dosing for common infection drug

NCT ID NCT06093269

Knowledge-focused Sponsor: University Hospital, Tours Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how the antibiotic cefazolin behaves in the blood of people on chronic hemodialysis who have catheter infections. Researchers will take blood samples at different times to measure drug levels. The goal is to find the best dose to treat infections while avoiding side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cefazolin
What this could lead to
If successful, this could help doctors give the right dose of cefazolin to hemodialysis patients, improving infection treatment and reducing side effects.
What could go wrong
This is a small, early-phase study with only 32 participants, so results may not apply to all patients. It focuses on drug levels, not direct treatment outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

32 people

The number who actually took part.

Started

Nov 2023

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Subjects aged 18 or over 2. On chronic intermittent dialysis 3. With a stated indication for initiation of cefazolin either: 1. For probabilistic treatment of a clinical presentation suggestive of MSSA infection 2. for treatment of Gram-positive cocci bacteremia 4. With the possibility of taking peripheral blood samples or samples from the dialysis machine until the next dialysis session at 48 hours. 5. Included within a maximum of one week after the first cefazolin injection. 6. Affiliated with French social security 7. Having signed an informed consent form Exclusion Criteria: 1. Pregnant or breast-feeding women 2. Dialysis lasting less than 3 hours, which most often corresponds to "acute" dialysis or the start of chronic dialysis, which fundamentally changes the elimination profile. 3. Allergy to cephalosporin and penicillin antibiotics (5-10% risk of cross-reactivity). 4. Non-anuric subjects with inhibitors of tubular creatinine secretion: 1. Curative-dose trimethoprim 2. Cimetidine 3. Ritonavir, Rilpivirine, Dolutegravir, Cobicistat 5. Subjects under guardianship, curatorship or safeguard of justice

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bacteremia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bacterial infectious disease bacterial infectious disease with sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hemodialysis catheter infection Infection, bacterial

Contacts and locations

Locations

  • Department of hemodialysis, University Hospital of Tours

    Orléans, 45100, France

  • Department of hemodialysis, University Hospital of Tours

    Tours, 37044, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.